2-溴-4-氯-6-氟苯甲醚 | 886499-78-1

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲醚系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-溴-4-氯-6-氟苯甲醚
• 英文名称: 1-bromo-5-chloro-3-fluoro-2-methoxybenzene
• 英文别名: 2-Bromo-4-chloro-6-fluoroanisole
• CAS: 886499-78-1
• 化学式: C₇H₅BrClFO
• 分子量: 239.472
• InChiKey: PPQUOMIZRVKTJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  二苯甲酮腙 、 2-溴-4-氯-6-氟苯甲醚 在 palladium diacetate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 6.0h， 以90%的产率得到1-(5-chloro-3-fluoro-2-methoxyphenyl)-2-(diphenylmethylene)hydrazine
  参考文献：
  名称：

  [EN] 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR
  [FR] ANTAGONISTES DE 7-HYDROXY-INDOLINYLE DU RÉCEPTEUR P2Y1

  摘要：

  本发明提供了Formula (I)的化合物：如规范中定义的Formula (I)，以及包含任何此类新化合物的组合物。这些化合物是P2Y1受体的拮抗剂，可用作药物。

  公开号：

  WO2014022343A1

文献信息

• 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150259286A1

  公开（公告）日：2015-09-17

  The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y 1 receptor which may be used medicaments.

  本发明提供了化合物(I)的公式：公式(I)如规范中定义的以及包含任何此类新型化合物的组成物。这些化合物是P2Y1受体的拮抗剂，可用作药物。
• Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling
  作者：Mark Zak、Emily J. Hanan、Patrick Lupardus、David G. Brown、Colin Robinson、Michael Siu、Joseph P. Lyssikatos、F. Anthony Romero、Guiling Zhao、Terry Kellar、Rohan Mendonca、Nicholas C. Ray、Simon C. Goodacre、Peter H. Crackett、Neville McLean、Christopher A. Hurley、Po-wai Yuen、Yun-Xing Cheng、Xiongcai Liu、Marya Liimatta、Pawan Bir Kohli、Jim Nonomiya、Gary Salmon、Gerry Buckley、Julia Lloyd、Paul Gibbons、Nico Ghilardi、Jane R. Kenny、Adam Johnson

  DOI：10.1016/j.bmcl.2019.04.008

  日期：2019.6

  Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
• EGFR INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3986895A1

  公开（公告）日：2022-04-27
• THERAPEUTIC EGFR INHIBITORS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20220135571A1

  公开（公告）日：2022-05-05

  The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.
• US9540323B2
  申请人：——

  公开号：US9540323B2

  公开（公告）日：2017-01-10